Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
ESMO 2024 – J&J eyes Rybrevant colorectal expansion
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
ESMO 2024 preview – Summit could take on Merck in breast cancer
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
